Latest news with #4DMolecularTherapeutics
Yahoo
16-05-2025
- Business
- Yahoo
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the compensation committee of the Company's board of directors granted eight new non-executive employees 31,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company. About 4DMT 4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Learn more at and follow us on LinkedIn. Contacts: Media: Jenn Gordondna CommunicationsMedia@ Investors: Julian PeiHead of Investor Relations and Corporate in to access your portfolio
Business Insider
10-05-2025
- Business
- Business Insider
Barclays Remains a Buy on 4D Molecular Therapeutics (FDMT)
In a report released on May 8, Gena Wang from Barclays maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of $38.00. The company's shares closed yesterday at $3.08. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wang is a 3-star analyst with an average return of 2.3% and a 39.26% success rate. Wang covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Legend Biotech. 4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.14, implying a 975.97% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $26.00 price target. Based on 4D Molecular Therapeutics' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1 thousand and a GAAP net loss of $49.67 million. In comparison, last year the company had a GAAP net loss of $32.28 million
Associated Press
27-03-2025
- Business
- Associated Press
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC Capital Markets 2025 Ophthalmology Conference being held virtually on April 3-4, 2025. Members of the management team will also be available for one-on-one meetings. RBC Capital Markets 2025 Ophthalmology Conference An archived copy of the webcast will be available for up to one year on the 'Investors' section of the 4DMT website at About 4DMT 4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Contacts: Media: Jenn Gordon dna Communications Investors: Julian Pei
Yahoo
02-03-2025
- Business
- Yahoo
4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations
Net loss: US$160.9m (loss widened by 60% from FY 2023). US$2.98 loss per share (further deteriorated from US$2.58 loss in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 97%. Earnings per share (EPS) also missed analyst estimates by 4.7%. Looking ahead, revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 2.4% from a week ago. We should say that we've discovered 4 warning signs for 4D Molecular Therapeutics (2 are potentially serious!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Globe and Mail
19-02-2025
- Business
- Globe and Mail
Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, NDA Approval, Epidemiology, Medication, Pipeline and Companies by DelveInsight
"Retinitis Pigmentosa Drugs Market" Retinitis Pigmentosa Companies such as Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Johnson & Johnson, MeiraGTx, Beacon Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeutics, ProQR Therapeutics, and Aldeyra Therapeutics and others. (Albany, USA) DelveInsight's ' Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast 2034 ' report delivers an in-depth understanding of historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. The Retinitis Pigmentosa market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Retinitis Pigmentosa market size from 2020 to 2034, segmented by seven major markets. The Retinitis Pigmentosa Market Report also covers current Retinitis Pigmentosa treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Retinitis Pigmentosa market. Key Takeaways from the Retinitis Pigmentosa Market Report In the US, the total number of prevalent cases of retinitis pigmentosa were ~113,000 in 2023. Nonsyndromic retinitis pigmentosa is more prevalent than syndromic retinitis pigmentosa with ~65% cases of total retinitis pigmentosa. X-linked retinitis pigmentosa in the US acoounted for ~16,000 prevalent cases in 2023. Germany has the most cases among EU4 and UK, whereas the UK has the fewest. RPE65-linked IRD account for about 3–16% of Leber congenital amaurosis and approximately 0.6–6% of retinitis pigmentosa. The leading Retinitis Pigmentosa Companies such as Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeutics, ProQR Therapeutics, and Aldeyra Therapeutics and others. Promising Retinitis Pigmentosa Therapies such as Botaretigene sparoparvovec, AGTC-501, GS030, 4D 125, CTx PDE6B, OCU 400, EA-2353, Ultevursen, ADX 2191, and others. June 2024:- Rolfs Consulting und Verwaltungs-GmbH (RCV)- Participants at risk for a syndromic or a monogenic genetic obesity, incl. participants clinically diagnosed with Bardet-Biedl-Syndrome (BBS). May 2024:- PYC Therapeutics- The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. May 2024:- Janssen Pharmaceutical- Phase 3 Study to Evaluate the Safety and Efficacy of for the Treatment of Japanese X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR). The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator ( Discover which therapies are expected to grab the Retinitis Pigmentosa Market Share @ Retinitis Pigmentosa Market Outlook Retinitis Pigmentosa Overview Retinitis Pigmentosa (RP) is a group of genetic disorders that cause progressive degeneration of the retina, the light-sensitive tissue at the back of the eye. This condition primarily affects the photoreceptor cells, namely rods and cones, leading to a gradual loss of vision. Initially, individuals with RP experience difficulty seeing in low light or at night (nyctalopia) and a reduction in peripheral vision, often described as tunnel vision. As the disease progresses, it can lead to central vision loss, making tasks like reading or recognizing faces challenging. RP is typically inherited and can result from mutations in any of more than 50 different genes. While there is currently no cure, various treatments, including vitamin A supplementation, retinal implants, and gene therapy, are being explored to slow the progression of the disease and improve patients' quality of life. Retinitis Pigmentosa Epidemiology Segmentation Total Retinitis Pigmentosa Diagnosed Prevalent Population Retinitis Pigmentosa Gender-Specific Diagnosed Prevalence Retinitis Pigmentosa Type-Specific Diagnosed Prevalence Sub-Type Specific Diagnosed Prevalence of Syndromic and Systemic Retinitis Pigmentosa Sub-Type Specific Diagnosed Prevalence of Non-Syndromic Retinitis Pigmentosa Download the report to understand which factors are driving Retinitis Pigmentosa Epidemiology trends @ Retinitis Pigmentosa Epidemiological Insights Retinitis Pigmentosa Treatment Landscape With only one approved therapies like LUXURNA, prompting exploration of off-label and symptomatic treatments, managing this progressive condition involves best supportive care, genetic counseling, and adaptive strategies. The potential therapies in the Retinitis Pigmentosa pipeline, including AGTC-501, Botaretigene sparoparvovec, MCO-010, GS030, ADX-2191, jCell, EA-2353, and others, are advancing through different stages of clinical development, offering promising avenues for effective Retinitis Pigmentosa treatments. Retinitis Pigmentosa Marketed Drugs LUXTURNA: Sparks Therapeutics (Roche)/Novartis LUXTURNA (AAV2-hRPE65v2; voretigene neparvovec), known as voretigene neparvovec-rzyl, is a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene. It provides a copy of the RPE65 gene to act in place of the mutated RPE65 gene. This working gene can restore vision and improve sight. The drug is administered as a subretinal single injection below the retina in patients who have confirmed RPE65 mutations and viable retinal cells. The drug was developed and commercialized in the US by Spark Therapeutics. In Europe, Novartis is currently marketing LUXTURNA as per a licensing agreement covering the development, registration, and commercialization rights of LUXTURNA in markets outside the US. Retinitis Pigmentosa Emerging Drugs Botaretigene sparoparvovec: Johnson & Johnson Innovative Medicine /MeiraGTx Botaretigene sparoparvovec (bota-vec) is designed to treat the most common form of X-linked retinitis pigmentosa (XLRP) caused by mutations in the eye-specific form of the RPGR gene called RPGR open reading frame 15 (RPGR ORF15). Both rods and cones photoreceptors require RPGR ORF15 to Phase I/II clinical trial of bota-vec in adult and pediatric patients is complete, and the Phase III Lumeos clinical trial completed enrollment in 2023. AAV-RPGR has received Fast Track and Orphan Drug designations from the FDA, as well as PRIME, ATMP, and Orphan Medicinal Product designations from the EMA. Currently, the drug is in the Phase III stage of its development for the treatment of X-linked Retinitis Pigmentosa. MCO-010: Nanoscope Therapeutics Nanoscope's MCO-010 gene therapy utilizes a convenient and well-established intraocular injection for delivery of a gene that encodes for the ambient light-sensitive MCO protein into retinal cells. These therapies are intended to enable retinal cells to detect light so that patients with retinitis pigmentosa or Stargardt disease may see again. MCO-010, is in clinical development for retinitis pigmentosa (RP) and Stargardt disease, which are two rare retinal diseases that cause blindness. MCO-010, recently reported topline results from the RESTORE Phase IIb multicenter, randomized, double-masked, sham-controlled clinical trial in the US for retinitis pigmentosa. The company has also recently completed the Phase II STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease. MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Download the report to understand which factors are driving growth in Retinitis Pigmentosa domain @ Retinitis Pigmentosa Market Dynamics and Trends Retinitis Pigmentosa Drug Market Optogenetics presents an innovative gene therapy overcoming the limitations of traditional approaches. It operates independently of specific genes and proves effective in late-stage diseases characterized by substantial photoreceptor loss. Retinitis pigmentosa is basically an inherited disease leading to a degeneration of the photoreceptor cells, disrupting the normal physiology of phototransduction. This may be autosomal dominant, autosomal recessive, X-linked, or maternally acquired. Mutations in pre-mRNA splicing cause autosomal dominant retinitis pigmentosa. Autosomal recessive RP is caused when two unaffected individuals who are carriers of the same RP-inducing gene in diallelic form can produce offspring with RP. X-linked RP is identified with mutations of six genes most commonly occurring at specific loci in the RPGR and RP2 genes. These multiple mutations are produced, causing the degeneration of photoreceptor cells. Retinitis Pigmentosa Market Outlook As more targetable mutations are discovered, and new targeted Retinitis Pigmentosa drugs are developed, patients and Opthamologists will have an expanding array of Retinitis Pigmentosa treatment options. Given the rapid pace of drug approvals, it is important to pause and ensure sufficient data supports the use of specific agents in the appropriate treatment settings, including adjuvant, consolidation, first-line, or subsequent therapy. Currently, LUXTURNA (voretigene neparvovec) is the only approved therapy for retinitis pigmentosa and is only authorized for the treatment of a small subpopulation of patients that have the RPE65 mutation. LUXTURNA gene therapy is designed for both adult and pediatric patients experiencing vision loss from Inherited Retinal Disease (IRD). Companies that focus on both adult and pediatric patients are likely to have a larger patient pool. Some key players pursuing this approach include Beacon Therapeutics (AGTC-501), MeiraGTx/Janssen Research & Development (Botaretigene sparoparvovec), 4D Molecular Therapeutics (4D-125), ProQR Therapeutics/Laboratoires Thea (Ultevursen), Coave Therapeutics (CTx-PDE6b), and Ocugen (OCU400). Retinitis Pigmentosa Market Dynamics The dynamics of the retinitis pigmentosa market are expected to change in the coming years. Gene therapy, available in the market, is utilized to address the effects of defective, disease-causing genes by employing engineered viruses, or viral vectors, to deliver a functional gene version into cells. The rising prevalence of retinitis pigmentosa worldwide has spurred pharmaceutical companies to explore this market, aiming for enhanced revenues through specific research and development strategies. Scope of the Retinitis Pigmentosa Market Report Coverage- 7MM Retinitis Pigmentosa Companies- Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeutics, ProQR Therapeutics, and Aldeyra Therapeutics and others. Retinitis Pigmentosa Therapies- Botaretigene sparoparvovec, AGTC-501, GS030, 4D 125, CTx PDE6B, OCU 400, EA-2353, Ultevursen, ADX 2191, and others. Retinitis Pigmentosa Market Dynamics: Retinitis Pigmentosa Market Drivers and Barriers Discover more about Retinitis Pigmentosa Drugs in development @ Retinitis Pigmentosa Clinical Trials Assessment Table of Content 1. Key Insights 2. Report Introduction 3. Executive Summary of Retinitis Pigmentosa (RP) 4. Retinitis Pigmentosa Market Overview at a Glance 5. Key Events 6. Epidemiology and Market Forecast Methodology 7. Retinitis Pigmentosa: Disease Background and Overview 8. Treatment of Retinitis Pigmentosa 9. Retinitis Pigmentosa Epidemiology and Patient Population 10. Patient Journey 11. Retinitis Pigmentosa Marketed Drugs 12. Retinitis Pigmentosa Emerging Drugs 13. Retinitis Pigmentosa: Market Analysis 14. Retinitis Pigmentosa Unmet Needs 15. Retinitis Pigmentosa SWOT Analysis 16. Retinitis Pigmentosa KOL Views 17. Retinitis Pigmentosa Market Access and Reimbursement 18. Appendix 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
